REGN241115P605000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Check Out What Whales Are Doing With REGN
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron, Sanofi Say Resubmitted Application to Expand Dupixent Label Accepted in U.S.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment
Express News | Sanofi - Resubmission Includes New Pivotal Data Which Confirm Dupixent Significantly Reduced Itch and Hive Activity
Express News | Dupixent® (Dupilumab) Sbla Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (Csu)
Wolfe Research Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,150
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Regeneron Pharma Initiated at Neutral by Citigroup
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Regeneron Announces Investor Conference Presentations
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry